Rodman & Renshaw Initiates Coverage on Orthovita (VITA) with a Market Outperform
More News related to VITA
- Orthovita to Present at the Piper Jaffray 21st Annual Health Care Conference
- Orthovita to Participate in the Lazard Capital Markets 6th Annual Healthcare Conference
- Orthovita Reports 2009 Third Quarter Financial Results
- Orthovita to Host Investor Breakfast on Wednesday, November 11, 2009 in San Francisco, CA
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
More News related to New Coverage
- C. K. Cooper & Company Initiates Coverage of UNIT Corporation (UNT)
- Morgan Stanley Initiates Coverage on ConAgra Foods (CAG) with a Equalweight
- Stifel Nicolaus Initiates Coverage on Simmons First National (SFNC) with a Hold
- Cowen & Co Initiates Coverage on Roche (RHHBY) with an Outperform
- BB&T Capital Initiates Coverage on MYR Group (MYRG) with a Hold
Rodman & Renshaw initiates coverage on Orthovita (Nasdaq: VITA) with a Market Outperform. Price target $4.
Rodman analyst says, "We believe the company is poised for steady 20%+ revenue growth, fueled by continued flow of clinical data supporting use of its Vitoss synthetic bone graft platform in an expanding set of indications, as well as new products. We also expect healthy sales and marketing leverage, helping narrow operating losses and positioning the company for profitability following 2H09 FDA approval of its Cortoss synthetic cortical bone. With Cortoss, the company enters a $280 million vertebral compression fracture implant market, among other indications, advancing the orthopaedic industry s 35+ year reliance on polymethylmethacrylate."
Orthovita, Inc. (Orthovita) is a spine and orthopedic biosurgery company with biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products.
Related Categories
New CoverageStocks Mentioned
+0.07Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
